Biliary Tract Neoplasms: all 492 studies
Page 3 of 5. Open to participants first (191), then studies with results posted, then the rest; newest registration first within each.
- A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic MetastasesCompletedNCT04338685Phase 1Results posted
- Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04234113Phase 1Results posted
- Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)TerminatedNCT04203160Phase 1/2Results posted
- Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract CancerTerminatedNCT04163900Phase 3Results posted
- Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract CancerCompletedNCT04072445Phase 2Results posted
- Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTCTerminatedNCT04066491Phase 2/3Results posted
- Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)TerminatedNCT04057365Phase 2Results posted
- Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)Active, not recruitingNCT03875235Phase 3Results posted
- M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)CompletedNCT03833661Phase 2Results posted
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)CompletedNCT03797326Phase 2Results posted
- A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract CancerTerminatedNCT03790111Phase 2Results posted
- Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract CancerCompletedNCT03785873Phase 1/2Results posted
- Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyCompletedNCT03639935Phase 2Results posted
- Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion PhaseCompletedNCT03531320Phase 1/2Results posted
- A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid TumorsCompletedNCT03314935Phase 1/2Results posted
- TAS-102 in Treating Advanced Biliary Tract CancersCompletedNCT03278106Phase 2Results posted
- Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)CompletedNCT03111732Phase 2Results posted
- Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract CancerCompletedNCT03101566Phase 2Results posted
- Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract CancerCompletedNCT03093870Phase 2/3Results posted
- Study of Nivolumab in Patients With Advanced Refractory Biliary Tract CancersCompletedNCT02829918Phase 2Results posted
- A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)CompletedNCT02821754Phase 2Results posted
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerActive, not recruitingNCT02711553Phase 2Results posted
- Pembrolizumab and GM-CSF in Biliary CancerCompletedNCT02703714Phase 2Results posted
- Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination ChemotherapyCompletedNCT02579616Phase 2Results posted
- Programs To Support You During ChemotherapyCompletedNCT02489422Not applicableResults posted
- A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerCompletedNCT02443324Phase 1Results posted
- Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 StudyTerminatedNCT01949870Phase 1Results posted
- A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract CancersCompletedNCT01943864Phase 2Results posted
- Tremelimumab With Chemoembolization or Ablation for Liver CancerCompletedNCT01853618Phase 1/2Results posted
- A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary CancersCompletedNCT01661114Phase 2Results posted
- Endoscopic Therapy of Malignant Bile Duct StricturesTerminatedNCT01543607Not applicableResults posted
- Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder CancerCompletedNCT01308840Phase 2Results posted
- A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract CancerTerminatedNCT00955721Phase 1/2Results posted
- A Study of Patients Receiving High-Dose Rate BrachytherapyCompletedNCT00924027Phase 2Results posted
- A Study of FOLFOX6 With Bevacizumab for Biliary System CarcinomaTerminatedNCT00881504Phase 2Results posted
- GTX Regimen for Biliary CancersTerminatedNCT00868998Phase 2Results posted
- Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract CancerCompletedNCT00753675Phase 2Results posted
- Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By SurgeryCompletedNCT00553332Phase 2Results posted
- Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract CancerCompletedNCT00380588Phase 2Results posted
- Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder CancerCompletedNCT00361231Phase 2Results posted
- Oxaliplatin and Capecitabine in Patients With Unresectable CholangiocarcinomaCompletedNCT00338988Phase 2Results posted
- Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)CompletedNCT00196105Not applicableResults posted
- HAIC Rechallenge in Biliary Tract Cancer and Colorectal Cancer Liver Metastases: Efficacy and Safety in Patients Resistant to Previous Systemic ChemotherapyCompletedNCT07830147
- Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.Active, not recruitingNCT07654530Phase 2
- Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract CancerActive, not recruitingNCT07635290Phase 2
- Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant TumorsCompletedNCT07319767
- Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical OutcomesCompletedNCT07252570
- Longitudinal Geriatric Vulnerability, Chemotherapy Toxicity, and Functional Outcomes in Older Adults With Gastrointestinal CancerCompletedNCT07184047
- Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract CancerSuspendedNCT07146646Phase 2
- A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC PatientsCompletedNCT07101874
- Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid TumorsActive, not recruitingNCT07021066Phase 1
- Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)Active, not recruitingNCT06975917
- ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompletedNCT06973161
- Comparison Between Winged Versus Traditional Plastic Stents for Biliary DrainageCompletedNCT06960733Not applicable
- Study for AZD4360 in Participants With Advanced Solid TumoursActive, not recruitingNCT06921928Phase 1/2
- XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Active, not recruitingNCT06792435Phase 1/2
- Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract CancerActive, not recruitingNCT06717464Phase 2
- EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)SuspendedNCT06653192Not applicable
- Agnostic Therapy in Rare Solid TumorsActive, not recruitingNCT06638931Phase 2
- AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerActive, not recruitingNCT06591520Phase 3
- Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTCActive, not recruitingNCT06490107Phase 2
- SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerActive, not recruitingNCT06465563Phase 2
- Nutritional Support for Patients Operated for Malignant Tumors in HPD ZoneCompletedNCT06397430Not applicable
- EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)SuspendedNCT06375967Not applicable
- Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar CholangiocarcinomaCompletedNCT06222619
- S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPActive, not recruitingNCT06188702Phase 1/2
- Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract CancerActive, not recruitingNCT06178445Phase 2
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)Active, not recruitingNCT06109779Phase 3
- Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresWithdrawnNCT06084689Phase 2
- Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC ImmunotherapyActive, not recruitingNCT06074029Phase 1/2
- Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic CholangiocarcinomaWithdrawnNCT06017297Phase 2
- GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract CancerTerminatedNCT05998447Phase 2
- Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 AntibodyActive, not recruitingNCT05994001Phase 1/2
- A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)CompletedNCT05924880Phase 3
- Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompletedNCT05835778
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)Active, not recruitingNCT05771480Phase 3
- A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract CancerCompletedNCT05742750Phase 1/2
- AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)Status unknownNCT05667350
- IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract CancerStatus unknownNCT05653180Phase 1/2
- Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract CarcinomaStatus unknownNCT05509478Phase 2
- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)Active, not recruitingNCT05506943Phase 2/3
- ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract CancerStatus unknownNCT05493878
- The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary MalignanciesStatus unknownNCT05487443Phase 2/3
- PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid TumorsStatus unknownNCT05357196Phase 1/2
- An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTCStatus unknownNCT05327582Phase 1/2
- Transparent Cap-assisted SpyGlass for Biliary StrictureStatus unknownNCT05320497Not applicable
- XmAb20717 in Advanced Biliary Tract CancersCompletedNCT05297903Phase 2
- Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTCCompletedNCT05254847Phase 2
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT05253053Phase 1/2
- Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract CancerCompletedNCT05239169Phase 2
- A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-upStatus unknownNCT05237193
- Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal CancersCompletedNCT05220046Phase 1
- TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract CancerCompletedNCT05190575Phase 2
- Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based TreatmentActive, not recruitingNCT05170438Phase 2
- Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerActive, not recruitingNCT05156788Phase 2
- A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid TumorsCompletedNCT05116891Phase 1/2
- A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Phase 1/2
- A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract CancerStatus unknownNCT05056116Not applicable
- Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract CancerCompletedNCT05052099Phase 1/2